Shares in ATAI Beckley, the London-listed biotechnology company, soared by as much as 42% in early trading on Thursday after the firm revealed positive results from its Phase 3 clinical trial of a psychedelic-assisted therapy for treatment-resistant depression. The stock closed the morning session at 287p, up from the previous close of 202p, making it the biggest riser on the AIM market today.
The trial, which enrolled over 200 patients across multiple centres in Europe and North America, met its primary endpoint: a statistically significant reduction in scores on the Montgomery–Åsberg Depression Rating Scale (MADRS) after three weeks, compared to the placebo group. The company stated that no serious adverse events were reported, reinforcing the safety profile of the treatment.
Analysts at Peel Hunt described the data as 'transformational' for the sector, noting that it could pave the way for regulatory submissions to the MHRA in the UK and the FDA in the US. 'This is a landmark moment for psychedelic medicine,' said Dr Emily Carter, senior healthcare analyst at Peel Hunt. 'If approved, this therapy could offer a new lifeline for the roughly one-third of depression patients who do not respond to existing treatments.'
The broader mental health and biotech indices also benefited from the news. The FTSE AIM All-Share Index rose 0.8%, while shares in other psychedelic-focused firms, such as Compass Pathways, gained 5% in sympathy trading. UK pension funds with exposure to AIM-listed healthcare stocks may see a modest uplift, though analysts caution that the sector remains highly speculative and subject to regulatory risk.
ATAI Beckley's surge comes amid growing global interest in psychedelic-assisted therapies, with the UK government having recently announced a £10 million funding package for mental health research. However, investors should be aware that even with positive trial data, the path to widespread clinical adoption remains lengthy, requiring further regulatory approvals and NHS commissioning decisions.